Key Insights

Highlights

Success Rate

67% trial completion

Treatment Research

5 treatments under study, led by Morphine

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 87/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

66.7%

-19.9% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

67% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Phase 2 (1)

Trial Status

Completed2
Terminated1

Trial Success Rate

66.7%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07484568Not ApplicableCompletedPrimary

Circuit Training With and Without Upper and Lower Limb Resistance Training in Post-CABG Patients

NCT04635852Phase 2Completed

Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Cancer Patients

NCT03148847TerminatedPrimary

Management of Cardiogenic Pulmonary Edema (RENAU-OAP)

Showing all 3 trials

Research Network

Common Treatments

  • Morphine1
  • Referentials Dissemination1
  • Circuit Training With Upper And Lower Limb Resistance Training1
  • Baseline Care1
  • Circuit Training Exercises1

Active Sponsors

  • University of Cologne1
  • Teva Branded Pharmaceutical Products R&D, Inc.1
  • Riphah International University1
  • Centre Hospitalier Annecy Genevois1

Top Investigators

Related Conditions

  • Cancer1
  • Heart Failure Left Sided1

Activity Timeline